Clinical trials: Stroke (CVA) or Transient Ischemic Attack
Suspected Arrhythmia, Palpitations
This Exploratory Medical Device Study Evaluated the Arrhythmia Diagnostic Yield of MEMO Patch V2, a Wearable Patch-type Electrocardiographic Monitor, in Adults With Suspected Arrhythmia Who Presented With Symptoms Such as Palpitations or Dizziness, or Who Had Cryptogenic Ischemic Stroke or Transient
This exploratory medical device study evaluated the arrhythmia diagnostic yield of MEMO Patch V2, a wearable patch-type electrocardiographic monitor, in adults with suspected arrhythmia who presented with symptoms such as…
- Conditions
- Suspected Arrhythmia, Palpitations, Dizziness, Cryptogenic Ischemic Stroke
- Trial name
- NCT07722026
- Testing
- MEMO Patch V2, 24-Hour Holter Monitor
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- HUINNO Co., Ltd
Transient Ischemic Attack
Lleida TIA Intervention Study
Having a transient ischemic attack (TIA) or a minor stroke is a real risk factor not only for early recurrent stroke but also for major extracranial vascular events.
- Trial name
- LLETIS (NCT04524078)
- Testing
- intensive integrated intervention care program
- Volunteers
- 100 people
- Sponsor
- Institut de Recerca Biomèdica de Lleida
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Transient Ischemic Attack, Non-disabling Stroke
Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT
The objective of the Program of Rehabilitative Exercise and Education to avert Vascular Events after Non-disabling stroke and Transient ischemic attack (PREVENT) Trial is to determine whether the timely delivery of secondary…
- Trial name
- PREVENT (NCT00885456)
- Testing
- PREVENT program, Usual Care
- Where
- 2 sites in Canada
- Volunteers
- 187 people
- Sponsor
- Marilyn MacKay-Lyons
Stroke, Ischemic Attack, Transient
Platelet Reactivity in Acute Non-disabling Cerebrovascular Events
Ticagrelor is a reversible and direct-acting oral antagonist of the P2Y12 (Purinergic receptor P2Y, G-protein coupled, 12) receptor for adenosine diphosphate, which provides faster, greater, and more consistent P2Y12 inhibition…
- Trial name
- PRINCE (NCT02506140)
- Testing
- Ticagrelor and Acetylsalicylic acid, Clopidogrel and Acetylsalicylic acid
- Where
- 25 sites in China
- Volunteers
- 675 people
- Sponsor
- Beijing Tiantan Hospital
Stroke, Transient Ischemic Attack
Smartwatch-Guided Secondary Prevention After Stroke
After a first stroke or transient ischemic attack (TIA), the risk of recurrence is high in the weeks and months following the initial event.
- Trial name
- WATCH-STEP (NCT07640360)
- Testing
- Smartwatch-Guided Secondary Prevention after Stroke
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Brest
Acute Stroke, TIA (Transient Ischemic Attack)
Sms-guided Training After Acute Stroke or Transient Ischemic Attack - a Randomized Controlled Trial
Eighty community-living individuals in Uppsala municipality will be included. Intervention: Outdoor walking exercise program and one strength exercise. Methods: Clinical assessments, questionnaires and medical records.
- Trial name
- SMS/TIA (NCT02902367)
- Testing
- Outdoor walking and strength exercise, control group
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Uppsala County Council, Sweden
Hypertension, Ischemic Stroke
Fimasartan Blood Pressure Lowering After Acute Stroke
This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients.
- Conditions
- Hypertension, Ischemic Stroke, Transient Ischemic Attack
- Trial name
- FABULOUS (NCT03231293)
- Where
- 27 sites in South Korea
- Volunteers
- 1,035 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Stroke
Effectiveness of Self-monitoring and Treatment of Blood Pressure Following Stroke or Transient Ischaemic Attack
This blinded end point RCT will recruit high risk TIA and mild stroke patients (through the emergency TIA clinics and the acute stroke services at the Norfolk \& Norwich University Hospital) who require anti-hypertensive therapy…
- Trial name
- TEST-BP (NCT02947490)
- Testing
- Self BP measurement, Standard Care, Standard BP management
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- University of East Anglia
Stroke
Post-Stroke Secondary Prevention With Digital Monitoring
Stroke is the second leading cause of death and a major cause of disability worldwide. In 2019, Disability-Adjusted Life-Years (DALYs) related to stroke was estimated to have reached 143 million.
- Trial name
- PSDM (NCT06837311)
- Testing
- Ecological Momentary Assessment (EMA), Biological assessment, Psychological examination and Substance Use symptomatology
- Where
- France
- Volunteers
- 388 people
- Sponsor
- University Hospital, Bordeaux
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Atrial Fibrillation, Stroke, Ischemic
Echocardiographic Predictors of Atrial Fibrillation
This prospective study aims to identify the diagnostic accuracy of echocardiographic predictors of atrial fibrillation in patients with ESUS (embolic stroke of undetermined source) or TIA (transient ischemic attack).
- Conditions
- Atrial Fibrillation, Stroke, Ischemic, Embolic Stroke of Undetermined Source, TIA, Brain
- Trial name
- EPAF-7 (NCT05044208)
- Testing
- ECG monitoring
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Karl Landsteiner University of Health Sciences
Ischemia Stroke, TIA (Transient Ischemic Attack)
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
This study aims to evaluate whether an upfront combination lipid-lowering therapy (statins combined with hybutimibe) can further improve the 8-week LDL-C target achievement rate (<1.8 mmol/L and ≥50% reduction from baseline)…
- Trial name
- NCT07908875
- Testing
- Atorvastatin, Hybutimibe 10mg QD
- Volunteers
- 520 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Brain Infarction, Transient Ischemic Attack
Aortic Arch Related Cerebral Hazard Trial (ARCH)
The ARCH is a controlled trial with a sequential design and with a prospective, randomized, open-label, blinded-endpoint (PROBE) methodology.
- Conditions
- Brain Infarction, Transient Ischemic Attack, Embolism
- Trial name
- ARCH (NCT00235248)
- Testing
- Warfarin, Clopidogrel-aspirin
- Where
- 2 sites in Australia, France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris